StrideBio, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Durham NC US

Primary Industry

Biotechnology

About

Based in North Carolina, US, StrideBio, Inc. was founded in 2015 by co-founders Patrick Ritschel, Aravind Asokan, and Mavis Agbandje. The company is a fully established gene therapy business focusing on developing genomic therapies for children and adults with life-changing or curative potential. The company raise its seed funding in June 2017, followed by series A funding in June 2018. In March 2021, the company raised its series B funding for USD 81.5 million. StrideBio therapies use a structure-inspired Adeno-associated virus AAV vector engineering technology to develop new and distinct vectors that improve on naturally occurring AAV serotypes to solve the existing shortcomings of first-generation gene therapies, allowing physicians to assure better patient results. The group intends to continue operational development and production capability expansion, leveraging its existing facilities, which include a 6,000 sq ft GMP clean suite in 2021.

Current Investors

Alexandria Venture Investments, Hatteras Venture Partners, Takeda Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Epidemiology

Website

www.stridebio.com

Verticals

HealthTech

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.